Low-dose Gamma Knife radiosurgery plus whole-brain radiation therapy for patients with 5 or more brain metastases with or without meningeal dissemination-Reference-Cited by-同舟云学术

Low-dose Gamma Knife radiosurgery plus whole-brain radiation therapy for patients with 5 or more brain metastases with or without meningeal dissemination

Published:2018-08-11 Issue:2 Volume:24 Page:161-167
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Miyakawa Akifumi^ORCID,Shibamoto Yuta,Takemoto Shinya,Hirai Tatsuo,Serizawa Toru

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s10147-018-1339-7/fulltext.html

Reference17 articles.

1. Shibamoto Y, Sugie C, Iwata H (2009) Radiotherapy for metastatic brain tumors. Int J Clin Oncol 14:281–288

2. Ohira S, Ueda Y, Akino Y et al (2018) HyperArc VMAT planning for single and multiple brain metastases stereotactic radiosurgery: a new treatment planning approach. Radiat Oncol 13:13

3. El Gantery MM, Abd El Baky HM, El Hossieny HA et al (2014) Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both. Radiat Oncol 9:116

4. Sperduto PW, Shanley R, Luo X et al (2014) Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1–3 brain metastases; poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys 90:526–531

5. Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk-reduction strategies for late complications arising from brain metastases treated with radiotherapy: a narrative review;Chinese Clinical Oncology;2022-04